Promepla announces the appointment of Jacques-Henry Grislain as CEO / Directeur Général

This appointment is marking a significant milestone in the company’s long-term growth strategy and is strengthening its leadership.

Michel Sasportes, President and Chairman and Marc Danchin, Administrator of Promepla, commented: “It is a decision we have carefully considered, reflecting our desire to provide Promepla with a clear long-term vision while continuing the Group’s development.”

   

Jacques-Henry Grislain brings extensive experience in the biotech and healthcare sectors, both in Europe and the US. Notably, he played a key role in the development of Amplitude Surgical, a leading orthopaedic implant manufacturer. He also gained early entrepreneurial experience by founding Mori (formerly Cambridge Crops), a biotech start-up focused on biomaterial science during his studies at MIT in Cambridge, MA – expertise that he will now leverage to support Promepla’s clients.